Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AG2304 vs Coadministration of AG23041 and AG23042 in Healthy Volunteers
NCT06916169Phase 1Not yet recruiting
- Sponsor
- Ahn-Gook Pharmaceutical Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules, Drug Delivery Systems
01
Overview
Phase 1, randomised, open-label trial of AG2304 in hypercholesterolemia (2 arms), sponsored by Ahn-Gook Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Curve at 72 hours and Maximum Plasma Concentration at 72 hours. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
AG2304
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06916169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916169.